Further, a study by Khalil et al. used a tissue microarray and postulated a role of the Wnt/β-catenin pathway in the early stages of HER2+ breast neoplasias [44], suggesting this pathway could also serve for future targeted therapies in GC, especially for HER2+ GC cases. Here, ERBB2 is linked to gastric cancer.